Inhibrx Biosciences (INBX) Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
INBX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Inhibrx Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$35.65 |
| 52 Week High | US$37.53 |
| 52 Week Low | US$10.81 |
| Beta | 0 |
| 1 Month Change | 26.51% |
| 3 Month Change | 78.79% |
| 1 Year Change | 133.46% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 156.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| INBX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.3% | 4.5% | 0.9% |
| 1Y | 133.5% | 0.5% | 18.4% |
Return vs Industry: INBX exceeded the US Biotechs industry which returned 0.5% over the past year.
Return vs Market: INBX exceeded the US Market which returned 18.4% over the past year.
Price Volatility
| INBX volatility | |
|---|---|
| INBX Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INBX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INBX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2024 | 159 | Mark Lappe | inhibrx.com |
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Inhibrx Biosciences, Inc. Fundamentals Summary
| INBX fundamental statistics | |
|---|---|
| Market cap | US$516.41m |
| Earnings (TTM) | -US$163.69m |
| Revenue (TTM) | US$1.40m |
Is INBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INBX income statement (TTM) | |
|---|---|
| Revenue | US$1.40m |
| Cost of Revenue | US$173.17m |
| Gross Profit | -US$171.77m |
| Other Expenses | -US$8.07m |
| Earnings | -US$163.69m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.30 |
| Gross Margin | -12,269.21% |
| Net Profit Margin | -11,692.43% |
| Debt/Equity Ratio | 144.8% |
How did INBX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/06 10:11 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inhibrx Biosciences, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Reni Benjamin | Citizens JMP Securities, LLC |
| Michael Yee | Jefferies LLC |